Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

  • FDA Panel Recommends Approval of Coherent Laser
Nov 1999
SANTA CLARA, Calif., Nov. 22 -- The Ophthalmic Drugs Subcommittee of the US Food and Drug Administration has recommended approval of Coherent Inc.'s Opal Photoactivator and Visudyne Therapy for use in treating the wet form of age-related macular degeneration (AMD). Both the panel and the FDA concluded that Visudyne therapy was most appropriate for patients with predominantly classic subfoveal choroidal neovascularization, as had been proposed by the treatment's co-developers, CIBA Vision -- the eye care unit of Novartis AG -- and QLT PhotoTherapeutics Inc.
Coherent and QLT PhotoTherapeutics jointly filed the New Drug Application for Visudyne therapy with the FDA on August 16, 1999. The application covers Coherent's Opal Photoactivator laser, a 689-nm diode laser developed specifically for use in photodynamic therapy, and Visudyne, the drug that is activated by the laser. CIBA Vision Corp. will market Visudyne worldwide.
The FDA will take the panel's recommendation into consideration during the completion of its review of the Visudyne application. The agency's final decision is expected by February 2, 2000.

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2016 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.